Dr Simpson is Co-director, MDA Neuromuscular Clinics and Director, ALS Clinical Research Division. Her clinical focus includes a wide range of neuromuscular disorders: Muscular Dystrophy, Myasthenia Gravis, Neuropathy, ALS, Inflammatory myopathy, mitochondrial and metabolic myopathy.
She is also education director of the Neurology residency program and Neuromuscular Medicine Fellowship Program. She has served as an writer for the American Academy of Neurology’s Residency In Service Training Examination Committee, and as an examiner for the American Board of Psychiatry and Neurology Part II Certification Board Exam. She currently serves as co-chair for the ALS/MND session of the American Academy of Neurology (AAN) and Sub-committee Chair of the Neurology Self-Assessment Examination (Annual Meeting Edition 2013) .
Clinical Expertise:
- Amyotrophic Lateral Sclerosis
- Myasthenia Gravis
- Peripheral Neuropathy/CIDP
- Muscular Dystrophy
- Mitochondrial Disorders
- Myopathy/Inflammatory Myopathy
Research Interests:
Characterize the peripheral immune inflammatory response in ALS and other neurodegenerative diseases and identify the potential markers that may reflect disease activity and progression. Translational research that leads to the identification and development of effective therapies aimed at positively altering the natural history of these diseases.
Education:
M.D. - University of Texas at Houston Medical School
Neurology Residency - Baylor College of Medicine, Houston TX
Physician Scientist Fellowship - Baylor College of Medicine, Houston TX
Board Certification:
American Board of Psychiatry and Neurology-recertified
American Board of Psychiatry and Neurology with Special Certification in Neuromuscular Medicine
Selected Publications:
- Miller RG, Moore DH, Forshew DA, Katz JS, Barohn RJ, Valan M, Bromberg MB, Goslin KL, Graves MC, McCluskey LF, McVey AL, Mozaffar T, Florence JM, Pestronk A, Ross M, Simpson EP, Appel SH; On behalf of the WALS Study Group. Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: Examining a more efficient trial design. Neurology. 2011 Aug 3
- Nicholson G, Lenk GM, Reddel SW, Grant AE, Towne CF, Ferguson CJ, Simpson E, Scheuerle A, Yasick M, Hoffman S, Blouin R, Brandt C, Coppola G, Biesecker LG, Batish SD, Meisler MH. Distinctive genetic and clinical features of CMT4J: a severe neuropathy caused by mutations in the PI(3,5)P2 phosphatase FIG4. Brain.2011 Jul;134(Pt 7):1959-71.
- Jawaid A, Poon M, Strutt AM, Rice LK, McDowell EJ, Salamone AR, Qureshi SU, Simpson E, Appel SH, York MK, Schulz PE. Does apolipoprotein E genotype modify the clinical expression of ALS? Eur J Neurol. 2011 Apr;18(4):618-24.
- Jawaid A, Murthy SB, Wilson AM, Qureshi SU, Amro MJ, Wheaton M, Simpson E,Harati Y, Strutt AM, York MK, Schulz PE. A decrease in body mass index is associated with faster progression of motor symptoms and shorter survival in ALS. Amyotroph Lateral Scler. 2010 Dec;11(6):542-8.
|
